Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Frequently asked questions
What sector does Nanobiotix S.A (NANO) operate in?
Nanobiotix S.A belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Nanobiotix S.A (NANO) current stock price?
As of the latest data, Nanobiotix S.A stock price is €33.18, with a previous close of €33.18.
What is Nanobiotix S.A (NANO) current market capitalization?
Nanobiotix S.A market cap is approximately 1.69 billion.
What is Nanobiotix S.A (NANO) Earnings Per Share (EPS)?
The trailing EPS is -€0.50, and the forward EPS is -€0.24.
Does Nanobiotix S.A (NANO) pay dividends?
No. Nanobiotix S.A does not pay a dividend.
When is Nanobiotix S.A (NANO) next earnings report?
Nanobiotix S.A is expected to release its next earnings report on June 30, 2026.
What is Nanobiotix S.A (NANO) beta (volatility) score?
Nanobiotix S.A has a beta of 0.560, indicating lower volatility than the overall market.
